EG BioMed has achieved a significant breakthrough in the field of pancreatic cancer detection with its innovative EG-Pancreatic Blood Test-E1 technology. This cutting-edge technology has received high praise from international experts and was prominently featured in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting under Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary. Additionally, it was reported in the Journal of Clinical Oncology, Volume 42, Number 16_suppl, marking a significant milestone for Taiwanese advancements in the global blood cancer medical field.
EG BioMed has filed a series of patent applications for its blood test technology targeting pancreatic cancer. A provisional application was submitted in the United States on February 17, 2023, with application number 63/485,748. The full U.S. patent application followed on February 16, 2024, under application number 18/444,053. Furthermore, a Global PCT application was filed on the same day with the application number PCT/AU2024/050116.
The EG-Pancreatic Blood Test-E1 has demonstrated outstanding performance, achieving an Area Under the Curve (AUC) value of 0.96. It boasts a specificity of 93.9% and a remarkable sensitivity of over 99% across all stages of pancreatic cancer, underscoring its potential to revolutionize pancreatic cancer diagnostics.